Showing results (51-60 of 102) with videos related to
Sort By:
Pageof 11
Frontiers in Oncology|November 12, 2015
Radiation-Induced Esophagitis is Mitigated by Soy IsoflavonesMatthew D Fountain, Lisa M Abernathy, Fulvio Lonardo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 27, 2025
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3Dwight H Owen, Nofisat Ismaila, Amith Ahluwalia, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2019
Profiling the Mutational Landscape in Known Driver Genes and Novel Genes in African American Non-Small Cell Lung Cancer PatientsChristine M Lusk, Donovan Watza, Greg Dyson, et al.Targeted Oncology|March 29, 2022
Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid TumorsAmita Patnaik, Shirish Gadgeel, Kyriakos P Papadopoulos, et al.Journal of Vascular and Interventional Radiology : JVIR|May 26, 2012
Percutaneous cryoablation of metastatic lesions from non-small-cell lung carcinoma: initial survival, local control, and cost observationsHyun J Bang, Peter J Littrup, Brandt P Currier, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 21, 2018
Using Radiolabeled 3'-Deoxy-3'-18F-Fluorothymidine with PET to Monitor the Effect of Dexamethasone on Non-Small Cell Lung CancerChristopher I McHugh, Monica R Thipparthi, Jawana M Lawhorn-Crews, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2007
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancerJohn V Heymach, Bruce E Johnson, Diane Prager, et al.BMC Cancer|July 25, 2024
Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II studyMichael Boyer, Rina Hui, Damien Urban, et al.Clinical Lung Cancer|February 4, 2018
Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic OncologyCesare Gridelli, Paul Baas, Fabrice Barlesi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 10, 2021
Outcomes According to ALK Status Determined by Central IHC or FISH in Patients with ALK-Positive NSCLC Enrolled in the Phase III ALEX StudyTony Mok, Solange Peters, D Ross Camidge, et al.Pageof 11